- Research article
- Open Access
- Open Peer Review
This article has Open Peer Review reports available.
PPARγ Pro12Ala polymorphism and risk of acute coronary syndrome in a prospective study of Danes
https://doi.org/10.1186/1471-2350-10-52
© Vogel et al; licensee BioMed Central Ltd. 2009
Received: 29 October 2008
Accepted: 07 June 2009
Published: 07 June 2009
Abstract
Background
Acute coronary syndrome (ACS) is a major cause of morbidity and mortality in the western world. Peroxisome proliferator-activated receptor γ (PPARγ) plays a key role in the regulation of the energy balance, adipocyte differentiation and lipid biosynthesis. The aim was to investigate if the polymorphism PPARγ2 Pro12Ala, which encodes a less efficient transcription factor, was associated with risk of acute coronary disease and if there were interactions between this polymorphism and factors that modify PPARγ activity, such as alcohol intake, smoking, and use of non-steroidal anti-inflammatory medicine.
Methods
A case-cohort study including 1031 ACS cases and a sub-cohort of 1703 persons was nested within the population-based prospective study Diet, Cancer and Health of 57,053 individuals.
Results
Homozygous male variant allele carriers of PPARγ2 Pro12Ala were at higher risk of ACS (HR = 2.12, 95% CI: 1.00–4.48) than homozygous carriers of the Pro-allele. Among men, there was a statistically significant interaction between genotypes and alcohol intake such that homozygous variant allele carriers with a low alcohol intake were at higher risk of ACS (HR = 25.3, CI: 16.5–38.7) compared to homozygous common allele carriers (p for interaction < 0.0001). Overall, the association was only observed among homozygous variant allele carriers. Thus, all the observed associations were obtained in subgroups including small numbers of cases. It is therefore possible that the observed associations were due to chance.
Conclusion
In the present study, there were no consistent associations between PPARγ Pro12Ala and risk of ACS, and no consistent interaction with alcohol, BMI, NSAID or smoking in relation to ACS.
Keywords
Background
Acute coronary syndrome (ACS) is a major cause of morbidity and mortality in the western world. Peroxisome proliferator-activated receptor γ (PPARγ) plays a key role in the regulation of the energy balance, adipocyte differentiation and lipid biosynthesis [1]. PPARγ regulates the expression of many adipose-specific genes via binding of a heterodimer of PPARγ and RXR (Retinoid × receptor) to regulatory response elements in target gene promoters [2].
The PPARγ Pro12Ala polymorphism results in a Pro to Ala amino acid substitution at codon 12 which is only present in the PPARγ2 isoform [2]. PPARγ2 is primarily expressed in adipose tissue. The polymorphism is the only commonly occurring missense polymorphism in Caucasians [2]. In vitro, the PPARγ2 Pro12Ala variant is a less active transcription factor, resulting in lower transcription levels of target genes [3–5]. There is evidence that the resulting mutant transcription factor profoundly affects the energy metabolism and energy balance linking the polymorphism to risk of diabetes mellitus [3, 6]. Thus, in a meta analysis variant Ala-allele carriers were at 20% lower risk of diabetes mellitus [7]. Variant Ala-allele carriers have also been reported to have higher insulin sensitivity [2].
Diabetes and overweight are risk factors for coronary heart disease and ACS, and therefore the PPARγ2 Pro12Ala variant could be associated with lower risk of coronary heart disease and ACS. Indeed, variant allele carriers of PPARγ2 Pro12Ala have been reported to be at lower risk of myocardial infarction in some studies [8, 9], but this was not confirmed in two prospective cohorts, where variant allele carriers were at higher risk of coronary heart disease than homozygous common allele carriers [10, 11]. The varying results may be explained by a low number of cases and thus limited statistical power but may also be explained by different distributions of potential effect modifiers in the study populations. A number of lifestyle factors could interact with PPAR-γ2 Pro12Ala in relation to risk of ACS including alcohol intake, use of non-steroidal anti-inflammatory drugs (NSAID), anthropometry and tobacco smoking. Moreover, interaction has been reported between the PPAR-γ2 Pro12Ala polymorphism and alcohol intake in relation to plasma levels of lipoproteins [12].
We hypothesized that carriers of the PPAR-γ2 Pro12Ala polymorphism would be at lower risk of ACS and that the association was be modified by alcohol consumption, smoking, NSAID use and body mass index (BMI). We have tested the hypothesis in a case-cohort study including 1031 cases with ACS and a random cohort sample of 1703 participants from the large prospective Diet, Cancer and Health cohort, encompassing 57 053 Danes.
Methods
Subjects
The subjects were selected from the Danish Diet, Cancer and Health study, an ongoing prospective cohort study [13]. Between December 1993 and May 1997, 160,725 individuals aged 50 to 64 years, born in Denmark, living in the Copenhagen and Aarhus areas were invited to participate in the study. A total of 57 053 persons accepted the invitation. At enrolment, detailed information on diet, lifestyle, weight, height, reproduction status, medical treatment, and other socio-economic characteristics and environmental exposures were registered. The questionnaire is described in detail elsewhere [13]. Blood, urine, and fat tissue was sampled and stored at -150°C.
A case-cohort study was designed using incident ACS, which includes unstable angina pectoris, fatal and non-fatal myocardial infarction as the outcome [14, 15]. Information on the disease endpoint was obtained by linkage with central Danish registries via the unique identification number assigned to all Danish citizens. Hospital records of potential cases were retrieved for participants who were registered with a first-time discharge diagnosis of ACS (ICD-8 codes 410–410.99, 427.27 and ICD-10 codes I20.0, I21.×, I46.×) in The Danish National Register of Patients, which covers all hospital discharge diagnoses since 1977 and all discharge diagnosis from out-patient clinics since 1995 (until Jan 1, 2004). Cases were classified according to symptoms, signs, coronary biomarkers, ECGs and/or autopsy findings in accordance with the current recommendations of the American Heart Association and the European Society of Cardiology (AHA/ECS) [14].
Further, linkage to the Cause of Death Register allowed for identification of participants with ACS coded as a primary or secondary cause of death (until Jan 1, 2004). In total, 1144 cases of ACS were identified and validated. The cohort sample included 1816 participants selected as a random sample of the entire cohort. This sample included 36 ASC cases. 183 samples were excluded because the last cases were identified after the time of sample retrieval or due to missing blood samples, and two participants were excluded due to failed genotyping. Thirteen cases and 13 controls were excluded due to lack of information on questionnaire data, leaving 1031 case subjects and 1703 participants in the sub-cohort including 34 cases who were also sub-cohort members for the analysis.
Alcohol, NSAID, and other lifestyle variables
In the food-frequency questionnaire, alcohol intake was recorded as the average frequency of intake of six types of alcoholic beverage over the preceding year: the frequency of consumption of three strengths of beer was recorded in bottles (330 ml), wine in glasses (125 ml), fortified wine in drinks (60 ml) and spirits in drinks (30 ml). The predefined responses were in twelve categories, ranging from "never" to "eight or more times a day". The alcohol content was calculated as follows: one bottle of light beer, 8.9 g ethanol; regular beer, 12.2 g ethanol; strong beer, 17.5 g ethanol; one glass of wine, 12.2 g ethanol; one drink of fortified wine, 9.3 g ethanol; and one drink of spirits, 9.9 g ethanol.
The lifestyle questionnaire included the following question regarding use of NSAID: Have you taken more than one pain relieving pill per month during the last year? If the answer was yes, the participant was asked to record how frequent they took each of the following types of medications: "Aspirin", "Paracetamol", "Ibuprofen", or "Other pain relievers". The latter category included NSAID preparations other than aspirin and ibuprofen. Based on all records, we classified study subjects according to their use of "any NSAID" (≥ 2 pills per month during one year) at baseline.
Data on hormone replacement therapy (HRT) was obtained from the lifestyle questionnaire and the participants were classified according to use HRT (never, past or current). Smoking status was recorded in three categories: never smoker, current smoker and former smoker.
At the study clinics, anthropometric measurements, including height and weight were obtained by professional staff members. BMI was calculated as weight (kg) per height squared (m).
Blood sampling and storage
From each non-fasting participant a total of 30 ml blood was collected in citrated (2 × 10 ml) and plain (1 × 10 ml) Venojects. Plasma, serum, lymphocytes, and erythrocytes were isolated and frozen at -20°C within 2 hours. At the end of the day of collection, all samples were stored in liquid nitrogen at -150°C.
Genotyping
DNA was isolated from frozen lymphocytes as described by Miller et al [16]. Generally, 100 μg DNA were obtained from 107 lymphocytes. PPAR2γ Pro12Ala (rs1801282) was genotyped as previously described [17]. Laboratory staff was blinded to the case/subcohort status of the subjects. Twenty ng of DNA were used for genotyping in 5 μl containing 1× Mastermix (Applied Biosystems, Nærum, Denmark), 100 nM probes, and 900 nM primers. Controls were included in each run, and repeated genotyping of a random 10% subset yielded 100% identical genotypes.
Measurement of blood lipids
Total Cholesterol and other blood lipids were measured on an Advia 1650 from Bayer Diagnostics, NY, USA. For total cholesterol kits ref. 01482198 were used. The interseriel variation was 1.1%. For triglyceride kits ref. 09580156 was used with an interserial variation of 4.5%. For HDL-cholesterol kits ref. 08058065 with an interseriel variation of 2.0%. LDL-cholesterol was calculated by Friedewald's formula.
Statistical methods
We used a case-cohort design with a sub-cohort of 1703 subjects drawn randomly, stratified on gender from the whole cohort with 57,053 subjects. A Cox proportional hazards model was used for analyses, as if the full cohort were included, modified by a weighting scheme described [18] and using a robust variance estimate. In the case-cohort design, weights are assigned to each subject, one for cases and N/n for non-cases in the sub-cohort, where N (n) is the number of non-cases in the cohort (sub-cohort). For women, N/n = 29,289/797 and for men, N/n = 26,012/906.
Age was used as the time scale in the Cox regression model. All models were sex specific and adjusted for baseline values of established risk factors for ACS including status of BMI, HRT, smoking status, NSAID use and alcohol intake.
We investigated possible interactions between polymorphism and alcohol intake, NSAID use, smoking status and BMI using the likelihood ratio test. Analyses were done using Stata version 9.2 (Stata Corporation, College Station, Texas, US).
Approval
Diet, Cancer and Health and the present sub-study were approved by the regional Ethics Committees on Human Studies in Copenhagen and Aarhus (File nos.(KF)11-037/01 and HKF-01-345/93), and by the Danish Data Protection Agency.
Results
Baseline characteristics of the study participants.
Women | Men | |||
|---|---|---|---|---|
Variablea | Cases (n = 245) | Cohort sample (n = 797) | Cases (n = 786) | Cohort sample (n = 906) |
Age at entry (yrs) | 60 (52–65) | 56 (51–64) | 58 (51–65) | 56 (51–64) |
BMI (kg/m2) | 26.4 (20.1–35.2) | 24.6 (19.7–33.7) | 26.9 (22.4–34.1) | 26.3 (21.6–32.4) |
Waist (cm) | 86 (69–107) | 80 (67–105) | 97 (83–117) | 95 (82–113) |
Diabetesb | ||||
Yes | 5.3% | 1.0% | 5.4% | 2.3% |
No | 90.2% | 94.3% | 88.5% | 91.7% |
Unknown | 4.5% | 4.7% | 6.1% | 6.0% |
Hypercholesterolemiab | ||||
Yes | 16.9% | 6.1% | 12.1% | 9.7% |
No | 44.0% | 48.4% | 45.4% | 52.0% |
Unknown | 39.1% | 45.5% | 42.5% | 38.3% |
Hypertension | ||||
Yes | 40.0% | 15.5% | 22.2% | 13.1% |
No | 51.8% | 74.9% | 61.0% | 72.4% |
Unknown | 8.2% | 9.6% | 16.8% | 14.5% |
Postmenopausal | ||||
Yes | 70.2% | 57.8% | N/A | N/A |
No | 5.3% | 17.5% | ||
Unknown | 24.5% | 24.7% | ||
HRT use | ||||
Current | 26.5% | 31.7% | N/A | N/A |
Former | 22.5% | 15.7% | ||
Never | 51.0% | 52.6% | ||
Smoking | ||||
Current | 59.2% | 36.8% | 59.3% | 37.3% |
Former | 16.3% | 21.4% | 26.5% | 35.4% |
Never | 24.5% | 41.8% | 14.2% | 27.3% |
Alcohol (g/d) | 6 (0–38) | 9 (0–40) | 17 (1–72) | 20 (1–83) |
Plasma lipids (mmol/L) | ||||
Triglycerides | 1.8 (0.9–4.7) | 1.3 (0.7–3.2) | 2.1 (0.9–5.3) | 1.7 (0.8–4.4) |
Cholesterol | 6.5 (4.8–8.6) | 6.0 (4.5–7.9) | 6.3 (4.6–8.1) | 5.9 (4.6–7.7) |
HDL-C | 1.6 (1.1–2.2) | 1.8 (1.2–2.6) | 1.3 (1.0–1.9) | 1.4 (1.0–2.1) |
The genotype distribution of PPARγ Pro12Ala was in Hardy-Weinberg equilibrium for both men and women in the cohort sample (results not shown). The allele frequency of the variant allele was 0.130 among men and 0.141 among women in the random sample. This is similar to the 0.14 found previously for another sample of the DHC cohort of 317 men and women matched on age and sex to 317 basal cell carcinoma cases [19].
Association between PPARγ Pro12Ala and risk of acute coronary syndrome among men and women in the Diet, Cancer and Health Cohort
PPARγ Pro12Ala | Ncase/Nnon-cases | HRa (95% CI) | p | HRb (95% CI) | p | HRc (95% CI) | p |
|---|---|---|---|---|---|---|---|
Men | |||||||
Pro/Pro | 589/664 | 1.0 | 1.0 | ||||
Pro/Ala | 176/204 | 0.92 (0.73–1.17) | 0.51 | 0.92 (0.72–1.18) | 0.50 | Not relevant | |
Ala/Ala | 21/12 | 1.99 (0.98–4.05) | 0.06 | 2.12 (1.00–4.48) | 0.05 | Not relevant | |
Pro/Ala & Ala/Ala | 197/216 | 0.98 (0.78–1.23) | 0.86 | 0.98 (0.77–1.24) | 0.86 | Not relevant | |
Women | |||||||
Pro/Pro | 181/581 | 1.0 | 1.0 | 1.0 | |||
Pro/Ala | 62/193 | 0.96 (0.67–1.36) | 0.80 | 0.93 (0.65–1.35) | 0.75 | 0.96 (0.67–1.40) | 0.85 |
Ala/Ala | 2/15 | 0.38 (0.08–1.72) | 0.21 | 0.37 (0.08–1.72) | 0.21 | 0.40 (0.08–1.85) | 0.24 |
Pro/Ala & Ala/Ala | 64/208 | 0.91 (0.65–1.29) | 0.60 | 0.89 (0.62–1.27) | 0.53 | 0.92 (0.64–1.33) | 0.60 |
HR for acute coronary syndrome subdivided by alcohol intake and PPARγ Pro12Ala genotype.
Ncases/Nnon-cases | HR (95% CI) | |||||
|---|---|---|---|---|---|---|
Alcohol intake g/day | Alcohol intake g/day | |||||
PPARγ Pro12Ala | < 4.0 | 4.0 < × < 12.0 | > 12.0 | < 4.0 | 4.0 < × < 12.0 | > 12.0 |
Men | ||||||
Pro/Pro | 98/81 | 127/128 | 364/455 | 1a | 0.86 (0.59–1.28) | 0.70 (0.50–0.98) |
Pro/Ala | 30/19 | 41/37 | 105/148 | 1.41 (0.73–2.70) | 0.90 (0.64–1.55) | 0.58 (0.39–0.86) |
Ala/Ala | 4/0 | 4/1 | 13/11 | 40.7 (27.5–60.2) | 2.30 (0.29–18.5) | 1.09 (0.46–2.57) |
P for interaction | p < 0.0001 | |||||
Pro/Pro | 98/81 | 127/128 | 364/455 | 1b | 0.91 (0.60–1.37) | 0.69 (0.49–0.99) |
Pro/Ala | 30/19 | 41/37 | 105/148 | 1.30 (0.67–2.55) | 0.78 (0.44–1.39) | 0.60 (0.39–0.90) |
Ala/Ala | 4/0 | 4/1 | 13/11 | 25.3 (16.5–38.7) | 3.18 (0.41–24.8) | 1.11 (0.45–2.76) |
P for interaction | p < 0.0001 | |||||
Women | ||||||
Pro/Pro | 76/157 | 50/205 | 55/219 | 1a | 0.52 (0.34–0.80) | 0.52 (0.34–0.79) |
Pro/Ala | 25/60 | 21/63 | 16/70 | 0.72 (0.41–1.27) | 0.70 (0.39–1.27) | 0.45 (0.23–0.88) |
Ala/Ala | 1/7 | 0/4 | 1/4 | 0.25 (0.29–2.15) | No estimate | 0.70 (0.08–6.50) |
P for interaction | 0.34 | |||||
Pro/Pro | 76/157 | 50/205 | 55/219 | 1b | 0.53 (0.34–0.83) | 0.51 (0.33–0.80) |
Pro/Ala | 25/60 | 21/63 | 16/70 | 0.73 (0.40–1.31) | 0.71 (0.38–1.31) | 0.44 (0.22–0.88) |
Ala/Ala | 1/7 | 0/4 | 1/4 | 0.27 (0.03–2.15) | No estimate | 0.52 (0.05–5.30) |
P for interaction | 0.46 | |||||
Pro/Pro | 76/157 | 50/205 | 55/219 | 1c | 0.53 (0.34–0.84) | 0.52 (0.33–0.82) |
Pro/Ala | 25/60 | 21/63 | 16/70 | 0.75 (0.41–1.35) | 0.72 (0.38–1.35) | 0.48 (0.24–0.86) |
Ala/Ala | 1/7 | 0/4 | 1/4 | 0.29 (0.03–2.59) | No estimate | 0.55 (0.05–5.71) |
P for interaction | 0.51 | |||||
There was no interaction between PPARγ Pro12Ala and BMI neither among men nor women (results not shown).
Risk of acute coronary syndrome in relation to use of NSAID. Aspirin users are included in 'No NSAID'
PPARγPro12Ala | Ncases/Nnon-cases | HRa 95% CI | HRb 95% CI | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Men | NSAID | NSAID | NSAID | |||||||
NO | YES | NO | YES | NO | YES | |||||
Pro/Pro | 531/622 | 58/42 | 1.00 | - | 1.63 | 1.07–2.47 | 1.00 | - | 1.58 | 1.00–2.48 |
Pro/Ala | 156/190 | 20/14 | 0.91 | 0.75–1.17 | 1.61 | 0.79–3.25 | 0.91 | 0.70–1.17 | 1.63 | 0.79–3.37 |
Ala/Ala | 20/11 | 1/1 | 2.07 | 0.99–4.32 | 2.00 | 0.13–30.5 | 2.36 | 1.09–5.13 | 1.10 | 0.07–17.7 |
P for interaction | 0.918 | 0.670 | ||||||||
Pro/Pro | 531/622 | 58/42 | 1.00 | - | 1.63 | 1.07–2.47 | 1.00 | - | 1.58 | 1.00–2.48 |
Pro/Ala & Ala/Ala | 176/201 | 21/15 | 0.96 | 0.77–1.24 | 1.62 | 0.72–3.23 | 0.97 | 0.76–1.25 | 1.60 | 0.79–3.23 |
P for interaction | 0.958 | 0.929 | ||||||||
Women | ||||||||||
Pro/Pro | 145/505 | 36/76 | 1.00 | - | 1.52 | 0.96–2.41 | 1.00 | - | 1.37 | 0.84–2.23 |
Pro/Ala | 52/168 | 10/25 | 0.99 | 0.67–1.45 | 1.31 | 0.59–2.87 | 0.93 | 0.62–1.38 | 1.33 | 0.59–3.00 |
Ala/Ala | 2/9 | 0/6 | 0.61 | 0.12–2.97 | - | - | 0.54 | 0.11–2.71 | - | - |
P for interaction | 0.771 | 0.924 | ||||||||
Pro/Pro | 145/505 | 36/76 | 1.00 | - | 1.42 | 0.96–2.41 | 1.00 | - | 1.36 | 0.84–2.23 |
Pro/Ala & Ala/Ala | 54/177 | 10/31 | 0.96 | 0.66–1.41 | 1.08 | 0.50–2.32 | 0.90 | 0.61–1.34 | 1.14 | 0.52–2.51 |
P for interaction | 0.517 | 0.875 | ||||||||
Male smokers were at almost 3-fold higher risk of ASC than non-smokers (additional file 1). There was no interaction between PPARγ Pro12Ala and smoking for men. Among women, there was interaction between PPARγ Pro12Ala and smoking status (p = 0.001). Variant allele carriers were at lower risk of ASC among never smokers and past smokers. There was no association between cholesterol levels and PPARγ Pro12Ala, and no interaction between PPARγ Pro12Ala and alcohol intake in relation to cholesterol levels or triglyceride levels (additional file 2).
Discussion
In this rather large, prospective study of the association between PPARγ Pro12Ala and risk of ACS, there was very little effect of the PPARγ Pro12Ala polymorphism. Homozygous variant allele carriers were at higher risk among men whereas the variant allele was associated with lower risk among women. The associations were only observed among homozygous carriers of the variant allele. Potential effect modification from intake of alcohol, use of NSAID, anthropometric variables and tobacco smoking was explored, but no consistent interactions were observed. All significant associations were observed in subgroups with small numbers of cases and limited power, indicating that the findings may be due to chance. The results are in agreement with a recent meta-analysis finding no association [20].
Our cases and controls were selected from the same cohort, which together with an almost complete follow-up of the participants minimized the risk for selection bias. For all participants, information on lifestyle factors was collected at enrolment, which minimized the risk for differential misclassification between the cases and controls. Furthermore, the use of only ACS cases confirmed through medical records ensured a high validity of our endpoint data.
We calculated separate risk estimates for men and women. This is partly because the risk of acute coronary heart disease is very different between the sexes, partly because some of the previous investigations were made among men only [9]. Also the prevalence of potential effect modifiers varied between the sexes in the present cohort. It has previously been reported that PPARγ Pro12Ala interact with the closely linked polymorphism PPARγ C14314T [8, 21, 22]. In the present cohort of Danes, the two polymorphisms are closely linked, with 84% of the genotypes being concordant and only 16% discordant [23]. We therefore made no attempt to differentiate between the effects of the two polymorphisms.
Among men, there was a statistically significant interaction between PPARγ Pro12Ala and alcohol intake. Among those who drank alcohol, variant allele carriers were at higher risk of ACS at all levels of alcohol intake but the association was strongest among participants with the lowest alcohol intake where heterozygous carriers were at 1.3-fold higher risk (95%CI: 0.67–2.55) of ACS than homozygous common allele carriers and homozygous variant allele carriers at 25.3 (95%CI: 16.5–38.7) times higher risk of ACS. These results are consistent with another prospective study [10], where male carriers of the variant allele were at 1.44-fold (95%CI: 1.00–2.07) higher risk than homozygous common allele carriers in a cohort where the average alcohol consumption among men was 7.0 g/day among controls and 5.9 g/day among cases. Information on alcohol consumption was not included in other studies [9, 24]. However, the present findings among those with a low alcohol intake rely on few cases, and among women no consistent effect modification was observed.
We were unable to reproduce a previously found interaction between PPARγ Pro12Ala and overweight in relation to coronary heart disease, where it was found that the variant allele was a stronger risk factor among overweight men and women [10]. We observed no interaction between PPARγ Pro12Ala and blood levels of cholesterol, or triglycerides, and no interaction with alcohol. Thus, we were also unable to reproduce a previously found interaction [12]. We have almost used the same cut-off value (4 g/day compared to 5 g/day), but the other study [12] included much younger individuals with lower cholesterol and triglyceride blood levels. Furthermore, the previous study did not subdivide by sex, although cholesterol levels differ by sex. Studies of mice, which were specifically deleted for the PPARγ2 isoform of PPARγ had the same bodyweight as common allele littermates when fed chow, but developed less adipose tissue when put on a high fat diet [25]. Thus, it is possible that the lack of associations for the PPARγ Pro12Ala is because of the relatively low fat diets among the present cohort members.
A number of commonly used NSAIDs activate PPARγ [26], and thus, if differences in PPARγ activity is related to risk of ACS, then interaction with NSAID use would be expected. We have previously observed interaction between PPARγ Pro12Ala and NSAID use in relation to risk of both breast cancer and lung cancer [17, 27] using the Diet, Cancer and Health cohort and the same definitions of NSAIDs as used here. No interaction between PPARγ Pro12Ala and NSAID use in relation to risk of ACS was, however, observed in this study. This indicates either that PPARγ activity is not related to risk of ACS, or that the activation of target genes in relation to risk of ACS is different than for cancer.
Among women, there was interaction between smoking status and PPARγ Pro12Ala. Variant allele carriers were at lower risk of ACS than homozygous common allele carriers among never and past smokers. We have previously observed the same pattern in relation to lung cancer, although there was no statistically significant interaction [27]. Among men, there seemed to be only additive effects of PPARγ Pro12Ala and smoking. Since the interaction among women relied on relatively few persons among non-smokers and variant allele carriers, the interaction observed may be a chance finding.
Conclusion
In conclusion, there were no convincing associations between PPARγ Pro12Ala and risk of ACS, and no systematic interaction with alcohol, BMI, NSAID or smoking in relation to ACS.
Declarations
Acknowledgements
We thank Anne-Karin Jensen for excellent technical support. This work was supported by the Danish Cancer Society, grant DP00027, Svend Andersen's Fond and the grant IMAGE from the Danish Ministry of Health, Research Centre for Environmental Health's Fund.
Authors’ Affiliations
References
- Heikkinen S, Auwerx J, Argmann CA: PPARgamma in human and mouse physiology. Biochim Biophys Acta. 2007, 1771: 999-1013.View ArticlePubMedPubMed CentralGoogle Scholar
- Meirhaeghe A, Amouyel P: Impact of genetic variation of PPARgamma in humans. Mol Genet Metab. 2004, 83: 93-102. 10.1016/j.ymgme.2004.08.014.View ArticlePubMedGoogle Scholar
- Stumvoll M, Haring H: The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes. 2002, 51: 2341-2347. 10.2337/diabetes.51.8.2341.View ArticlePubMedGoogle Scholar
- Masugi J, Tamori Y, Mori H, Koike T, Kasuga M: Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun. 2000, 268: 178-182. 10.1006/bbrc.2000.2096.View ArticlePubMedGoogle Scholar
- Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998, 20: 284-287. 10.1038/3099.View ArticlePubMedGoogle Scholar
- Tonjes A, Stumvoll M: The role of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma in diabetes risk. Curr Opin Clin Nutr Metab Care. 2007, 10: 410-414. 10.1097/MCO.0b013e3281e389d9.View ArticlePubMedGoogle Scholar
- Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, et al: The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. 2000, 26: 76-80. 10.1038/79839.View ArticlePubMedGoogle Scholar
- Doney AS, Fischer B, Leese G, Morris AD, Palmer CN: Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a Go-DARTS study. Arterioscler Thromb Vasc Biol. 2004, 24: 2403-2407. 10.1161/01.ATV.0000147897.57527.e4.View ArticlePubMedGoogle Scholar
- Ridker PM, Cook NR, Cheng S, Erlich HA, Lindpaintner K, Plutzky J, Zee RY: Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol. 2003, 23: 859-863. 10.1161/01.ATV.0000068680.19521.34.View ArticlePubMedPubMed CentralGoogle Scholar
- Pischon T, Pai JK, Manson JE, Hu FB, Rexrode KM, Hunter D, Rimm EB: Peroxisome proliferator-activated receptor-gamma2 P12A polymorphism and risk of coronary heart disease in US men and women. Arterioscler Thromb Vasc Biol. 2005, 25: 1654-1658. 10.1161/01.ATV.0000171993.78135.7e.View ArticlePubMedGoogle Scholar
- Li L, Cheng LX, Nsenga R, He MA, Wu TC: Association between Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma 2 and myocardial infarction in the Chinese Han population. Clin Cardiol. 2006, 29: 300-304. 10.1002/clc.4960290706.View ArticlePubMedGoogle Scholar
- Brand-Herrmann SM, Kuznetsova T, Wiechert A, Stolarz K, Tikhonoff V, Schmidt-Petersen K, Telgmann R, Casiglia E, Wang JG, Thijs L, et al: Alcohol intake modulates the genetic association between HDL cholesterol and the PPARgamma2 Pro12Ala polymorphism. J Lipid Res. 2005, 46: 913-919. 10.1194/jlr.M400405-JLR200.View ArticlePubMedGoogle Scholar
- Tjonneland A, Olsen A, Boll K, Stripp C, Christensen J, Engholm G, Overvad K: Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population-based prospective cohort study of 57,053 men and women in Denmark. Scand J Public Health. 2007, 35: 432-441. 10.1080/14034940601047986.View ArticlePubMedGoogle Scholar
- Joensen AM, Jensen MK, Overvad K, Dethlefsen C, Schmidt E, Rasmussen L, Tjonneland A, Johnsen S: Predictive values of acute coronary syndrome discharge diagnoses differed in the Danish National Patient Registry. J Clin Epidemiol. 2009, 62: 188-194. 10.1016/j.jclinepi.2008.03.005.View ArticlePubMedGoogle Scholar
- Jensen MK, Rimm EB, Rader D, Schmidt EB, Sorensen TI, Vogel U, Overvad K, Mukamal KJ: S447X variant of the lipoprotein lipase gene, lipids, and risk of coronary heart disease in 3 prospective cohort studies. Am Heart J. 2009, 157: 384-390. 10.1016/j.ahj.2008.10.008.View ArticlePubMedPubMed CentralGoogle Scholar
- Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988, 16: 1215-10.1093/nar/16.3.1215.View ArticlePubMedPubMed CentralGoogle Scholar
- Vogel U, Christensen J, Nexo BA, Wallin H, Friis S, Tjonneland A: Peroxisome profilerator-activated receptor{gamma}2 Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis. 2007, 28: 427-434. 10.1093/carcin/bgl170.View ArticlePubMedGoogle Scholar
- Kalbfleisch JD, Lawless JF: Likelihood analysis of multi-state models for disease incidence and mortality. Statistics in Medicine. 1988, 7: 149-160. 10.1002/sim.4780070116.View ArticlePubMedGoogle Scholar
- Vogel U, Christensen J, Wallin H, Friis S, Nexo BA, Tjonneland A: Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutat Res. 2007, 617: 138-146.View ArticlePubMedGoogle Scholar
- Zafarmand MH, Schouw van der YT, Grobbee DE, de Leeuw PW, Bots ML: Peroxisome proliferator-activated receptor gamma-2 P12A polymorphism and risk of acute myocardial infarction, coronary heart disease and ischemic stroke: a case-cohort study and meta-analyses. Vasc Health Risk Manag. 2008, 4: 427-436.PubMedPubMed CentralGoogle Scholar
- Doney A, Fischer B, Frew D, Cumming A, Flavell DM, World M, Montgomery HE, Boyle D, Morris A, Palmer CN: Haplotype analysis of the PPARgamma Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genet. 2002, 3: 21-10.1186/1471-2156-3-21.View ArticlePubMedPubMed CentralGoogle Scholar
- Doney AS, Fischer B, Cecil JE, Boylan K, McGuigan FE, Ralston SH, Morris AD, Palmer CN: Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes. Diabetologia. 2004, 47: 555-558. 10.1007/s00125-003-1323-1.View ArticlePubMedGoogle Scholar
- Vogel U, Christensen J, Dybdahl M, Friis S, Hansen RD, Wallin H, Nexo BA, Raaschou-Nielsen O, Andersen PS, Overvad K, et al: Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. Mutation Research. 2007, 624: 88-100.View ArticlePubMedGoogle Scholar
- Swarbrick MM, Chapman CM, McQuillan BM, Hung J, Thompson PL, Beilby JP: A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-gamma 2 is associated with combined hyperlipidaemia in obesity. Eur J Endocrinol. 2001, 144: 277-282. 10.1530/eje.0.1440277.View ArticlePubMedGoogle Scholar
- Zhang J, Fu M, Cui T, Xiong C, Xu K, Zhong W, Xiao Y, Floyd D, Liang J, Li E, et al: Selective disruption of PPARgamma 2 impairs the development of adipose tissue and insulin sensitivity. Proc Natl Acad Sci USA. 2004, 101: 10703-10708. 10.1073/pnas.0403652101.View ArticlePubMedPubMed CentralGoogle Scholar
- Tegeder I, Pfeilschifter J, Geisslinger G: Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 2001, 15: 2057-2072. 10.1096/fj.01-0390rev.View ArticlePubMedGoogle Scholar
- Vogel U, Christensen J, Wallin H, Friis S, Nexo BA, Raaschou-Nielsen O, Overvad K, Tjonneland A: Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res. 2008, 639: 89-100.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/10/52/prepub
Pre-publication history
Copyright
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
